Results 61 to 70 of about 5,494 (193)
Advanced Science, EarlyView.PCSK9 upregulation in cerebrovascular endothelial cells and microglia destabilizes the Aβ transporter LRP1, while TRIB3‐associated autophagy blockade further limits intracellular Aβ degradation. A RAP‐modified tea‐polyphenol nanoparticle co‐delivers siPCSK9 and siTRIB3 to restore LRP1‐mediated Aβ efflux and autophagy‐dependent degradation, reducing Aβ ...
Jie Miao +8 more
wiley +1 more source
, 2021 Background Aducanumab is a human monoclonal antibody that selectively targets aggregated forms of amyloid beta (Aβ), including soluble oligomers and insoluble fibrils, and, at the writing of this , is currently under review by the US Food and Drug ...
Porter, Verna R. +15 more
core +1 more source
ESC Heart Failure, Volume 12, Issue 2, Page 1119-1131, April 2025.Abstract Large clinical data underscore that heart failure is independently associated to an increased risk of negative cognitive outcome and dementia. Emerging evidence suggests that cerebral hypoperfusion, stemming from reduced cardiac output and vascular pathology, may contribute to the largely overlapping vascular dementia and Alzheimer's disease ...
Mauro Massussi +6 more
wiley +1 more source
Aducanumab: A fate undecided [PDF]
Chemical & Engineering News, 2020 Few drug development tales have had the twists and turns of aducanumab , Biogen’s antibody treatment for Alzheimer’s disease.
openaire +1 more source
Aducanumab, Accelerated Approvals & the Agency: Why the FDA Needs Structural Reform [PDF]
The US Food and Drug Administration’s controversial decision to grant accelerated approval to aducanumab (Aduhelm), a therapy for Alzheimer’s disease, has motivated multiple policy reforms.
Herder, Matthew
core +3 more sources
Alzheimer's &Dementia, Volume 22, Issue 10, October 2026.Abstract Since the groundbreaking work of Alois Alzheimer in the early 1900s, Alzheimer's disease research has evolved immensely, most notably with the establishment of the Alzheimer's Disease Research Centers (ADRC). Fueled by the vision and funding of the National Institute on Aging (NIA), ADRCs have created a legacy through their work standardizing ...
John H. Growdon +4 more
wiley +1 more source
Practical Considerations in the Administration of Aducanumab for the Neurologist
Neurology Clinical Practice, 2022 Aducanumab (Aduhelm), developed by the biotechnology firm Biogen in Cambridge, MA, was approved using the less common accelerated approval pathway by the Federal Drug Administration (FDA) reserved for treatments that fill a significant unmet need.1 Its approval on June 7, 2021, has been met with an outpouring of opinions from prescribers, insurers ...
Coerver, Katherine +4 more
openaire +2 more sources
Dementia with Lewy bodies and amyloid pathology: Eligible for anti‐amyloid treatment or not?
Alzheimer's &Dementia, Volume 22, Issue 10, October 2026.Abstract In the future, treatment of dementia will be personalized, targeted to contributing pathologies, rather than the clinical syndrome. Anti‐amyloid drugs for Alzheimer's disease are the first approved drugs; however, the impact of co‑pathology on the treatment effects remains incomplete.
Lieza G Exalto +6 more
wiley +1 more source
Aducanumab: The first targeted Alzheimer's therapy
Drug Discoveries & Therapeutics, 2021 Alzheimer's disease (AD) is an irreversible brain disorder associated with severe progressive dementia and is characterized by deposits of amyloid plaques in the brain. Over the past 20 years, the mortality of strokes and heart disease has decreased, but deaths from AD have increased. The four drugs used clinically to treat AD can only relieve symptoms
Yang, Pan, Sun, Fusheng
openaire +3 more sources
Journal of Pharmacoeconomics and Pharmaceutical Management, 2022 Alzheimer’s disease (AD) is a neurodegenerative disease and the most common cause of dementia affecting millions of people yearly. On June 7, 2021, the U.S FDA granted accelerated approval to highly expensive Aducanumab (Aduhelm), the first-ever disease-
Santenna Chenchula, Padmavathi R.
doaj